Workflow
白云山板蓝根
icon
Search documents
九州通九信中药品牌重塑战略正式启动
Cai Jing Wang· 2025-08-24 14:26
根据项目规划,九信中药将从四个维度推进品牌重塑:一是品牌战略层面,明确品牌的核心定位,构建 清晰品牌架构,提炼品牌文化故事,强化品牌差异化认知;二是产品战略层面,根据市场深度调研梳理 明确产品线,建立"明星单品+利润产品+基础产品"三级产品线体系,重点打造明星单品;三是视觉形 象层面,全面升级品牌Logo与IP形象,融合道地基因与现代审美理念,重构包装系统,强化终端识别与 消费体验;四是传播推广层面,整合线上线下资源,通过内容营销、媒体联动、终端活化等多元方式, 系统传递品牌价值,提升消费者信任与口碑。 8月21日,九州通九信中药品牌重塑项目启动仪式在九州通集团总部大厦圆满举行。 作为此次九信中药品牌重塑的战略合作伙伴,上海桑迪品牌咨询有限公司深耕医药健康领域品牌战略咨 询15年,曾成功服务云南白药、同仁堂、广药白云山等近300家行业标杆企业,打造了豹七三七粉、白 云山板蓝根、朗迪钙等众多明星单品。上海桑迪品牌咨询有限公司创始人、董事长、首席品牌官张继明 在发言中表示,桑迪将以"成就行业标杆品牌"为目标,依托丰富的大健康品牌打造经验,结合九信中药 全产业链优势,帮助企业厘清战略方向,打造核心产品集群,建立符合 ...
广药原董事长李楚源被“双开”:搞迷信活动,非法收受巨额财物
Guan Cha Zhe Wang· 2025-05-17 09:13
Group 1 - The Guangdong Provincial Commission for Discipline Inspection and Supervision has initiated an investigation into Li Chuyuan, the former Party Secretary and Chairman of Guangzhou Pharmaceutical Group, for serious violations of discipline and law [1][2] - Li Chuyuan is accused of losing faith, being disloyal to the Party, and failing to implement inspection rectification requirements, among other misconducts [1][2] - He has been found to violate multiple regulations, including accepting gifts, attending banquets, and misusing public resources [1][2] Group 2 - Li Chuyuan's actions constitute severe violations of political, organizational, and ethical discipline, leading to his expulsion from the Party and removal from public office [2] - His case has been forwarded to the prosecution for legal review, and he faces the revocation of various honors and awards [2] - Li Chuyuan has a long career in the pharmaceutical industry, holding various significant positions within Guangzhou Pharmaceutical Group and its subsidiaries [2][3] Group 3 - Controversial statements made by Li Chuyuan during public forums have drawn criticism, including claims about the health benefits of certain products [3] - His resignation from the position of Chairman of Guangzhou Pharmaceutical Group was submitted for personal reasons, effective July 22, 2024 [3][4] - The ongoing investigation and disciplinary actions against Li Chuyuan reflect broader issues of governance and accountability within the pharmaceutical industry [1][2][4]